Literature DB >> 30853819

Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib.

Barbara Melosky1, Parneet Cheema2, Geoffrey Liu3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30853819      PMCID： PMC6380641          DOI： 10.3747/co.26.4809

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  3 in total

Review 1.  Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Authors:  B Melosky; P Cheema; J Agulnik; R Albadine; D G Bebb; N Blais; R Burkes; C Butts; P B Card; A M Y Chan; V Hirsh; D N Ionescu; R Juergens; W Morzycki; Z Poonja; R Sangha; M Tehfe; M S Tsao; M Vincent; Z Xu; G Liu
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

2.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Authors:  Dong-Wan Kim; Marcello Tiseo; Myung-Ju Ahn; Karen L Reckamp; Karin Holmskov Hansen; Sang-We Kim; Rudolf M Huber; Howard L West; Harry J M Groen; Maximilian J Hochmair; Natasha B Leighl; Scott N Gettinger; Corey J Langer; Luis G Paz-Ares Rodríguez; Egbert F Smit; Edward S Kim; William Reichmann; Frank G Haluska; David Kerstein; D Ross Camidge
Journal:  J Clin Oncol       Date:  2017-05-05       Impact factor: 44.544

3.  Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  D Ross Camidge; Hye Ryun Kim; Myung-Ju Ahn; James Chih-Hsin Yang; Ji-Youn Han; Jong-Seok Lee; Maximilian J Hochmair; Jacky Yu-Chung Li; Gee-Chen Chang; Ki Hyeong Lee; Cesare Gridelli; Angelo Delmonte; Rosario Garcia Campelo; Dong-Wan Kim; Alessandra Bearz; Frank Griesinger; Alessandro Morabito; Enriqueta Felip; Raffaele Califano; Sharmistha Ghosh; Alexander Spira; Scott N Gettinger; Marcello Tiseo; Neeraj Gupta; Jeff Haney; David Kerstein; Sanjay Popat
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.